Additional Hetero Ring Attached Directly Or Indirectly To The Four-membered Hetero Ring By Nonionic Bonding Patents (Class 514/210.19)
-
Publication number: 20090325925Abstract: This invention provides thiophene compounds of formula I: wherein R1, R2, R3, R4, n, p, and m are as described in the specification. The compounds are inhibitors of PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.Type: ApplicationFiled: January 26, 2009Publication date: December 31, 2009Applicant: Millennium Pharmaceuticals, Inc.Inventors: Christelle C. Renou, Tricia J. Vos, Matthew O. Duffey, Robert Downham
-
Publication number: 20090247503Abstract: Provided herein are 5-demethoxyfumagillol and its derivatives. Also provided herein are methods of making the 5-demethoxyfumagillol and derivatives. Also provided herein are biological activities of the 5-demethoxyfumagillol and derivatives and methods of using same for treating diseases.Type: ApplicationFiled: March 25, 2009Publication date: October 1, 2009Applicants: Versitech Limited, Morningside Ventures LimitedInventors: Dan Yang, Chengyong Li, Shiwu Chen
-
Patent number: 7579340Abstract: The present invention relates to urotensin II receptor antagonists, CCR-9 antagonists, pharmaceutical compositions containing them and their use.Type: GrantFiled: August 22, 2007Date of Patent: August 25, 2009Assignee: Pfizer IncInventors: Ronald Biediger, Jie Chen, Daxin Gao, Robert Market, Chengde Wu
-
Publication number: 20090209512Abstract: Disclosed is an agent comprising a benzothiophene alkyl ether derivative represented by the general formula below or a salt thereof: wherein R1 and R2 independently represent at least one group selected from a hydrogen atom, a halogen atom, an alkyl group, an aryl group, an aralkyl group, an alkoxy group, an aryloxy group, an alkylthio group, an arylthio group, an alkenyl group, an alkenyloxy group, an amino group, an alkylsulfonyl group, an arylsulfonyl group, a carbamoyl group, a heterocyclic group, an amino group, a hydroxyl group, a carboxyl group, a nitro group, an oxo group and the like; R3 represents an alkylamino group which may be substituted or an amino or hydroxyl group which may be protected; and m and n independently represent an integer ranging from 1 to 6. The agent is useful as a neurogenesis inducer or a therapeutic agent for neuropathy.Type: ApplicationFiled: February 13, 2009Publication date: August 20, 2009Applicant: Toyama Chemical Co., Ltd.Inventors: Noboru IWAKAMI, Shigeki MARUBUCHI, Tomohiro OKUDA
-
Publication number: 20090186868Abstract: A compound represented by the general formula (1) [X1 and X2 represent hydrogen atom, a halogen atom, hydroxyl group and the like, R1 represents a phenyl group, R2 represents an alkyl group, an alkenyl group, or an alkoxy group, R3 represents hydrogen atom, a halogen atom, hydroxyl group, or an alkoxy group, R4 represents hydrogen atom, or an alkyl group, Z1 and Z2 represent hydrogen atom, a halogen atom, hydroxyl group and the like, Z3 represents cyano group, an alkyl group, an alkenyl group and the like, Z4 represents an alkyl group, an alkenyl group, an alkynyl group and the like, and represents a single bond or a double bond], which shows high antitumor effect against cancer cells including drug resistant cells.Type: ApplicationFiled: October 24, 2006Publication date: July 23, 2009Applicant: Daiichi Sankyo Company LimitedInventors: Kouichi Uoto, Yasuyuki Takeda, Atsunobu Sakamoto, Yoshihiro Takayanagi
-
Publication number: 20090093453Abstract: Disclosed is an agent comprising a benzothiophene alkyl ether derivative represented by the general formula below or a salt thereof: wherein R1 and R2 independently represent at least one group selected from a hydrogen atom, a halogen atom, an alkyl group, an aryl group, an aralkyl group, an alkoxy group, an aryloxy group, an alkylthio group, an arylthio group, an alkenyl group, an alkenyloxy group, an amino group, an alkylsulfonyl group, an arylsulfonyl group, a carbamoyl group, a heterocyclic group, an amino group, a hydroxyl group, a carboxyl group, a nitro group, an oxo group and the like; R3 represents an alkylamino group which may be substituted or an amino or hydroxyl group which may be protected; and m and n independently represent an integer ranging from 1 to 6. The agent is useful as a neurogenesis inducer or a therapeutic agent for neuropathy.Type: ApplicationFiled: April 24, 2007Publication date: April 9, 2009Applicant: Toyama Chemical Co., LtdInventors: Noboru Iwakami, Shigeki Marubuchi, Tomohiro Okuda
-
Publication number: 20090069250Abstract: The present invention relates to a novel class of compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and sale dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.Type: ApplicationFiled: February 23, 2007Publication date: March 12, 2009Inventors: Jonathan B. Grimm, Jed L. Hubbs, Thomas Miller, Karin M. Otte, Phieng Siliphaivanh, Matthew G. Stanton, Kevin Wilson, David Witter, Hua Zhou
-
Publication number: 20090054396Abstract: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cancer.Type: ApplicationFiled: September 8, 2008Publication date: February 26, 2009Applicant: ASTRAZENECA ABInventors: Susan Ashwell, Thomas Gero, Stephanos Ioannidis, James Janetka, Paul Lyne, Vibha Oza, Mei Su, Dingwei Yu, Stephanie Springer
-
Publication number: 20090018114Abstract: The present application relates to cannabinoid receptor ligands containing compounds of formula (I) wherein A, R1, R2, and R3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.Type: ApplicationFiled: July 8, 2008Publication date: January 15, 2009Applicant: ABBOTT LABORATORIESInventors: William A. Carroll, Michael J. Dart, Arturo Perez-Medrano, Derek W. Nelson
-
Publication number: 20090018113Abstract: The present application relates to a novel cyclopenta[b]benzofuran derivatives, processes for their preparation and their use for the manufacture of medicaments, in particular for the prophylaxis and/or therapy of acute or chronic disorders characterized by elevated cellular stress, by local or systemic inflammatory processes or by hyperproliferation.Type: ApplicationFiled: May 14, 2005Publication date: January 15, 2009Applicant: Bayer HealthCare AGInventors: Nicole Diedrichs, Thomas Fahrig, Irene Gerlach, Jaques Ragot, Joachim Schuhmacher, Kai Thede, Ervin Horvath
-
Patent number: 7456164Abstract: The invention relates to 3- or 4-monosubstituted phenol and thiophenol derivatives of formula (I) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. Said 3- or 4-monosubstituted phenol and thiophenol derivatives are H3 ligands and are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.Type: GrantFiled: May 9, 2005Date of Patent: November 25, 2008Assignee: Pfizer, IncInventors: Patrick Bernardelli, Andrew Michael Cronin, Alexis Denis, Stephen Martin Denton, Henry Jacobelli, Mark Ian Kemp, Edwige Lorthiois, Fiona Rousseau, Delphine Serradeil-Civit, Fabrice Vergne
-
Publication number: 20080207588Abstract: The present invention is concerned with certain novel derivatives of Formula I, wherein R, R1 to R10 are as described in the specification, and at least one CR5R6, or CR7R8, or CR9R10 is a an optionally substituted azetidine ring or an optionally substituted oxetan ring, which may be useful in the manufacture of pharmaceutical compositions for treating disorders mediated by lipoxygenases. They may also be useful in the manufacture of pharmaceutical formulations for the treatment of lipoxygenase mediated disorders.Type: ApplicationFiled: December 9, 2005Publication date: August 28, 2008Inventors: Daniel T. W. Chu, Donald R James, Bing Wang
-
Publication number: 20080113945Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.Type: ApplicationFiled: August 20, 2007Publication date: May 15, 2008Applicant: Sequoia Pharmaceuticals, Inc.Inventors: Michael Eissenstat, Dehui Duan
-
Publication number: 20080064677Abstract: The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behcet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.Type: ApplicationFiled: July 24, 2006Publication date: March 13, 2008Inventors: Ashis K. Saha, Nili Schutz, Anurag Sharadendu, Dilara McCauley, Mercedes Lobera, Yael Marantz, Jian Lin, Srinivasa Rao Cheruku, Pini Orbach, Anurag Sharadendu, Robert Christian Penland, Kimberley Gannon, Sharon Shacham, Silvia Noiman, Oren Becker
-
Patent number: 7342043Abstract: An alkyl ether derivative represented by the formula: wherein R1, R2, R3, R4, m and n are as defined in the specification, or salts thereof exhibits synergistically improved anti-hypoxic activity when combined with a compound having an acetylcholine esterase inhibitory activity. Therefore, the combination according to the present invention is useful as a method for improving cerebral function. Further, a pharmaceutical composition containing the compound relating to the combination according to the present invention is useful for treatment and prevention of dysfunction of cerebral acetylcholine neurons in the sequelae of cerebrovascular dementia, senile dementia, Alzheimer's disease and ischemic cerebral lesion and in the cerebral apoplexy or the memory impairment caused by selective neuronal death.Type: GrantFiled: April 3, 2003Date of Patent: March 11, 2008Assignee: Toyama Chemical Co., Ltd.Inventors: Yasushi Nakada, Masaya Nakagawa, Satoshi Ono
-
Patent number: 7288538Abstract: The present invention relates to urotensin II receptor antagonists, CCR-9 antagonists, pharmaceutical compositions containing them and their use.Type: GrantFiled: August 23, 2004Date of Patent: October 30, 2007Assignee: Encysive Pharmaceuticals, Inc.Inventors: Chengde Wu, Daxin Gao, Ronald Biediger, Jie Chen, Robert V. Market
-
Publication number: 20070173487Abstract: The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behcet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.Type: ApplicationFiled: July 24, 2006Publication date: July 26, 2007Inventors: Ashis K. Saha, Nili Schutz, Anurag Sharadendu, Dilara McCauley, Mercedes Lobera, Yael Marantz, Jian Lin, Srinivasa Rao Cheruku, Pini Orbach, Anurag Sharadendu, Robert Christian Penland, Kimberley Gannon, Sharon Shacham, Silvia Noiman, Oren Becker
-
Patent number: 7214701Abstract: The invention relates to insecticidal mixtures for protecting plants against attack by pests comprising (a) compounds of the formula (I) ?in which W, X, Y, Z, A, B, D and G are each as defined in the disclosure, and (b) specified agonists or antagonists of nicotinic acetylcholine receptors.Type: GrantFiled: June 25, 2004Date of Patent: May 8, 2007Assignee: Bayer CropScience AGInventors: Reiner Fischer, Christoph Erdelen
-
Patent number: 7132414Abstract: The present invention relates to pharmaceutical compositions containing, as active ingredient, a compound of formula: in which R1 represents a radical —NHCOR4 or —N(R5)—Y—R6, Y is CO or SO2, R4 represents a radical -alk-SO2—R11, -alk-SO2—CH?CH—R11 or Het substituted with —SO2—R11 or a phenyl radical substituted with —SO2—R11 or -alk-SO2—R11, R5 represents a hydrogen atom or an alkyl radical, R6 represents a phenylalkyl, Het or Ar radical, to the novel derivatives of formula (I) and to their preparation, as well s to their use in treating various disorders of the nervous system.Type: GrantFiled: February 4, 2004Date of Patent: November 7, 2006Assignee: Aventis Pharma S.A.Inventors: Daniel Achard, Herve Bouchard, Jean Bouquerel, Bruno Filoche, Serge Grisoni, Augustin Hittinger, Michael R. Myers
-
Patent number: 7087594Abstract: An alkyl ether represented by the general formula: or its salt. This compound has activity to protect neurons, activity to accelerate nerve regeneration and activity to accelerate neurite extension and hence is useful as a therapeutic agent for diseases in central and peripheral nerves.Type: GrantFiled: October 18, 2002Date of Patent: August 8, 2006Assignee: Toyama Chemical Co., Ltd.Inventors: Akihito Saitoh, Noboru Iwakami, Tamotsu Takamatsu
-
Patent number: 6872717Abstract: A method of treating or preventing obesity, this method comprising administering to a patient in need of such treatment an effective amount of a compound of formula in which R, R3 and R4 are as defined in the specification.Type: GrantFiled: September 12, 2002Date of Patent: March 29, 2005Assignee: Aventis Pharma S.A.Inventors: Daniel Achard, Hervé Bouchard, Jean Bouquerel, Bruno Filoche, Serge Grisoni, Augustin Hittinger, Michael R. Myers
-
Patent number: 6864276Abstract: The invention relates to insecticidal mixtures for protecting plants against attack by pests comprising (a) compounds of the formula (I) ?in which W, X, Y, Z, A, B, D and G are each as defined in the disclosure, and (b) agonists or antagonists of nicotinic acetylcholine receptors.Type: GrantFiled: May 7, 2001Date of Patent: March 8, 2005Assignee: Bayer Cropscience AGInventors: Reiner Fischer, Christoph Erdelen
-
Patent number: 6858603Abstract: Disclosed are azetidine derivatives of formula: their optical isomers, their salts, their preparation and medicaments containing them.Type: GrantFiled: December 16, 2002Date of Patent: February 22, 2005Assignee: Aventis Pharma S.A.Inventors: Daniel Achard, Hervé Bouchard, Jean Bouquerel, Marc Capet, Serg Grisoni, Jean-Luc Malleron, Serge Mignani, Augustin Hittinger
-
Patent number: 6846817Abstract: The invention provides nicotine receptor agonists of formula I: wherein R1, x, y, and n have any of the values given in the specification, or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions comprising such a compound or salt, methods for preparing such a compound or salt, and methods for modulating (e.g. antagonizing or activating) nicotine receptors with such a compound or salt.Type: GrantFiled: November 30, 2001Date of Patent: January 25, 2005Assignee: Regents of the University of MinnesotaInventor: S. Mbua Ngale Efange
-
Publication number: 20040116400Abstract: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.Type: ApplicationFiled: July 17, 2003Publication date: June 17, 2004Applicants: CYTOKINETICS, INC., SMITHKLINE BEECHAM CORPORATIONInventors: Andrew McDonald, Gustave Bergnes, David J. Morgans, Dashyant Dhanak, Steven David Knight
-
Patent number: 6750213Abstract: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.Type: GrantFiled: April 11, 2002Date of Patent: June 15, 2004Assignee: Merck & Co., Inc.Inventors: Frank P. DiNinno, Jane Y. Wu, Seongkon Kim, Helen Y. Chen
-
Publication number: 20040106595Abstract: 2H-1-Benzopyran derivatives, processes for their preparation and use thereof for the preparation of pharmaceutical compositions for the prevention and treatment of postmenopausal pathologies.Type: ApplicationFiled: December 22, 2003Publication date: June 3, 2004Inventors: Maurizio Delcanale, Gabriele Amari, Elisabetta Armani, Maurizio Civelli, Elisabetta Galbiati
-
Patent number: 6734176Abstract: The present invention relates to pharmaceutical compositions containing, as active ingredient, a compound of formula: in which R1 represents a radical —NHCOR4 or —N(R5)—Y—R6, Y is CO or SO2, R4 represents a radical -alk-SO2—R11, -alk-SO2—CH═CH—R11 or Het substituted with —SO2—R11 or a phenyl radical substituted with —SO2—R11 or -alk-SO2—R11, R5 represents a hydrogen atom or an alkyl radical, R6 represents a phenylalkyl, Het or Ar radical, to the novel derivatives of formula (I) and to their preparation, as well s to their use in treating various disorders of the nervous system.Type: GrantFiled: December 17, 2002Date of Patent: May 11, 2004Assignee: Aventis Pharma S.A.Inventors: Daniel Achard, Hervé Bouchard, Jean Bouquerel, Bruno Filoche, Serge Grisoni, Augustin Hittinger, Michael R. Myers
-
Publication number: 20040053989Abstract: The invention provides methods to treat neurological disorders such as Alzheimer's disease, or to slow the progression of such diseases, or to treat and/or prevent other disorders as disclosed in the specification, by administering to patients, or delivering to the tissues of such patients, oltipraz or related compounds as disclosed in the specification.Type: ApplicationFiled: July 2, 2003Publication date: March 18, 2004Applicant: Patrick PrendergastInventors: Patrick T. Prendergast, Paul Armstrong
-
Publication number: 20040038957Abstract: The invention relates to dual molecules formed from coupling products complying with the formula 1Type: ApplicationFiled: February 4, 2003Publication date: February 26, 2004Inventors: Bernard Meunier, Anne Robert, Odile Dechy-Cabaret, Francoise Benoit-Vical
-
Publication number: 20040019084Abstract: The invention concerns novel lipoic acid derivatives, which have an inhibiting action with respect to NO-synthase enzymes producing nitrogen monoxide NO and/or are agents enabling the regeneration of antioxidants or entities trapping reactive oxygen species (ROS) and intervening in a more general manner in the redox status of thiol groups. The invention also concerns methods for preparing them, pharmaceutical compositions containing them and their use for therapeutic purposes, particularly their use as NO-synthase inhibitors and/or as agents acting more generally in the redox status of thiol groups.Type: ApplicationFiled: April 21, 2003Publication date: January 29, 2004Applicant: SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S)Inventors: Jeremiah Harnett, Michel Auguet, Pierre-Etienne Chabrier de Lassauhyere
-
Publication number: 20040014740Abstract: Novel anthelmintic compositions containing thiophene derivatives as active ingredients are disclosed.Type: ApplicationFiled: May 28, 2003Publication date: January 22, 2004Inventors: Byung Hyun Lee, Timothy G. Geary, John P. Davis, Jerry W. Bowman
-
Publication number: 20030158175Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.Type: ApplicationFiled: October 2, 2002Publication date: August 21, 2003Applicant: WyethInventors: Lynne Padilla Greenblatt, Michael Gerard Kelly
-
Patent number: 6566356Abstract: The present invention relates to pharmaceutical compositions containing, as active ingredient, a compound of formula: in which R1 represents a radical —NHCOR4 or —N(R5)—Y—R6, Y is CO or SO2, R4 represents a radical -alk-SO2—R11, -alk-SO2—CH═CH—R11 or Het substituted with —SO2—R11 or a phenyl radical substituted with —SO2—R11 or -alk-SO2—R11, R5 represents a hydrogen atom or an alkyl radical, R6 represents a phenylalkyl, Het or Ar radical, to the novel derivatives of formula (I) and to their preparation.Type: GrantFiled: March 2, 2001Date of Patent: May 20, 2003Assignee: Aventis Pharma S.A.Inventors: Daniel Achard, Hervé Bouchard, Jean Bouquerel, Bruno Filoche, Serge Grisoni, Augustin Hittinger, Michael R. Myers
-
Patent number: 6555569Abstract: A pharmaceutical composition containing a glycogen phosphorylase inhibitor of Formula I or IA as defined herein is administered to a mammal to treat infection.Type: GrantFiled: February 16, 2001Date of Patent: April 29, 2003Assignee: Pfizer Inc.Inventors: Joyce A. Sutcliffe, Judith Lee Treadway
-
Publication number: 20030073680Abstract: The present invention provides amino ceramide-like compounds which inhibit glucosyl ceramide (GlyCer) formation by inhibiting the enzyme GlyCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels.Type: ApplicationFiled: April 29, 2002Publication date: April 17, 2003Applicant: The Regents of The University of MichiganInventors: James A. Shayman, Norman S. Radin
-
Patent number: 6518264Abstract: Disclosed are azetidine derivatives of formula: their optical isomers, their salts, their preparation and medicaments containing them.Type: GrantFiled: March 9, 2001Date of Patent: February 11, 2003Assignee: Aventis Pharma S.A.Inventors: Daniel Achard, Hervé Bouchard, Jean Bouquerel, Marc Capet, Serg Grisoni, Jean-Luc Malleron, Serge Mignani, Augustin Hittinger
-
Patent number: 6489354Abstract: The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4c, R4d, and R4f are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-3 and/or CCR-5.Type: GrantFiled: March 1, 2000Date of Patent: December 3, 2002Assignee: Merck & Co., Inc.Inventors: Jianming Bao, Robert K. Baker, William H. Parsons, Kathleen Rupprecht
-
Publication number: 20020168405Abstract: Bacterial infections may be treated using a high dosage regimen of amoxycillin and potassium clavulanate.Type: ApplicationFiled: April 4, 2002Publication date: November 14, 2002Applicant: Beecham Pharmaceuticals (Pte) LimitedInventors: Creighton P. Conley, John A. Roush, Kevin H. Storm
-
Patent number: 6479479Abstract: Compounds of formula: in which R represents a CR1R2, C═C(R5)SO2R6 or C═C(R7)SO2alk radical, their preparation and the pharmaceutical compositions containing them.Type: GrantFiled: March 2, 2001Date of Patent: November 12, 2002Assignee: Aventis Pharma S.A.Inventors: Daniel Achard, Hervé Bouchard, Jean Bouquerel, Bruno Filoche, Serge Grisoni, Augustin Hittinger, Michael R. Myers
-
Publication number: 20020137736Abstract: There are provided novel compounds of formula (I) 1Type: ApplicationFiled: February 27, 2001Publication date: September 26, 2002Inventors: Kenneth Mattes, Robert Murray, Eifion D Phillips, Hans Schmitthenner
-
Patent number: 6355631Abstract: The present invention relates to pharmaceutical compositions containing, as an active ingredient, at least one compound of formula: in which R1 represents a radical —N(R4)R5, —N(R4)—CO—R5, —N(R4)—SO2R6 or one of its pharmaceutically acceptable salts, to the novel derivatives of formula (I), to their pharmaceutically acceptable salts and to their preparation.Type: GrantFiled: March 2, 2001Date of Patent: March 12, 2002Assignee: Aventis Pharma S.A.Inventors: Daniel Achard, Hervé Bouchard, Jean Bouquerel, Bruno Filoche, Serge Grisoni, Augustin Hittinger, Michael R. Myers